Cwm LLC Raises Holdings in Novo Nordisk A/S $NVO

Cwm LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 35.0% during the 3rd quarter, Holdings Channel reports. The fund owned 145,793 shares of the company’s stock after buying an additional 37,795 shares during the period. Cwm LLC’s holdings in Novo Nordisk A/S were worth $8,090,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. NewSquare Capital LLC raised its stake in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $37,000. State of Wyoming bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth $38,000. Maseco LLP bought a new position in shares of Novo Nordisk A/S in the 2nd quarter worth $39,000. Finally, Copeland Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 47.3% during the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on NVO shares. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Hsbc Global Res downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Finally, Jefferies Financial Group started coverage on Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $53.33.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approved Novo’s oral Wegovy pill, broadening how patients can take its leading GLP‑1 weight‑loss therapy and opening a large new addressable market for oral treatment forms. Novo Nordisk’s Wegovy Pill Wins U.S. Approval
• Positive Sentiment: Early analyst/coverage pieces highlight strong efficacy data for the oral Wegovy (noted mean weight loss and high share of patients >20% weight loss), positioning the pill as a potential market‑share and growth driver versus rivals. Novo Nordisk: Oral Weight-Loss To The Rescue
• Positive Sentiment: Market reaction: some outlets report a strong short‑term rally (double‑digit intraday moves in recent sessions) after the pill approval, reflecting renewed investor optimism about sales upside. Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK
• Positive Sentiment: Coverage suggests the FDA nod could lift healthcare ETFs and related peers as the oral GLP‑1 opportunity reshapes the sector, a tailwind for investor flows into NVO and peers. The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
• Positive Sentiment: Reports say Novo is pricing the oral Wegovy to undercut Eli Lilly in direct‑to‑consumer channels — a deliberate share‑capture strategy that should speed adoption even if it compresses unit economics. With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market
• Neutral Sentiment: Interest/attention indicators: NVO is a trending stock on investor screens — increased search and mention volume can amplify short‑term volatility but isn’t a fundamental read. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Competitive landscape: coverage notes heightened rivalry with Eli Lilly (new oral entrants and filings). Competition increases execution risk but also validates a large market. The Weight Loss Drug Competition Is Heating Up
• Negative Sentiment: Pricing pressure in China: Novo has cut Wegovy prices in some Chinese provinces — reports say prices were nearly halved in places as the company preempts generic competition; this raises near‑term revenue and margin risk in a large market. Novo cuts Wegovy prices in some Chinese provinces, local media reports Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat

Novo Nordisk A/S Trading Down 1.9%

Novo Nordisk A/S stock opened at $51.40 on Tuesday. The firm has a market cap of $229.51 billion, a PE ratio of 14.94 and a beta of 0.67. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The stock’s 50 day simple moving average is $49.27 and its two-hundred day simple moving average is $56.41. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.